الفهرس 
? Giant Cell Tumor of BoneOnly 14 pages are availabe for public view
 |  | from | 105 |  |  |
| | | from | 105 | | |
Abstract
Background: Giant cell tumor of bone (GCT) is a locally aggressive osteolytic lesion. It is a rare, generally benign tumor of limb bones that can cause metastases, especially in the lung as well as significant bone destruction.
Aim of the work: The aim of this study was to review the literature about the use of denosumab vs zoledronic acid in treatment of GCT regarding their efficacy and oncological effects.
Patients and Methods: The present study was a systematic review and meta-analysis for comparing the use of Denosumab and Zoledronic acid in treatment of giant cell tumor of bone and the aim of the study was to review the literature about the use of denosumab vs zoledronic acid in treatment of GCT regarding their efficacy and oncological effects.
Results: Based on the results of the current study we found that Denosumab had a statistically significant higher efficacy than ZA but no significance found regarding duration of recovery, While there was no statistically significant difference between the side effects of Denosumab and Zoledronic acid in treatment of giant cell tumor of bone regarding fatigue, back pain, loss of appetite, anemia, infection, kidney injury, nausea, hypocalcemia, hypophosphatemia, constipation and fever, although Zoledronic acid showed more evidence of side effects than densomab in some side effects as anorexia, anemia, kidney injury, nausea, hypophosphatemia, constipation and fever but was of no statistical significance.
Conclusion: We can say that both the denosumab and zoledronic acid treatments led to marked reductions in giant cell tumor of bone, with relatively manageable adverse effects. Denosumab is novel, as an antiresorptive agent and more effective, safer though higher cost than zoledronic acid for treating patients with surgically unsalvageable giant cell tumor of bone.